Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pathai Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.pathai.com
Year Founded: 2016
Status: Private
BioCentury | May 7, 2024
Deals
Deals report: Novartis strengthens radiotherapy pipeline with pair of deals
Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
BioCentury | Jun 15, 2023
Management Tracks
Kite’s Huston joins Galapagos as CFO, COO
Plus: Burgess to head BD at Cerevel, and updates from Mablink, PathAI and Berlin
BioCentury | Feb 18, 2023
Management Tracks
CEO Christi Shaw leaving Gilead’s Kite
Plus: MorphoSys’ Lee named CFO at Vir, and updates from Novo Nordisk, PathAI, PhRMA and NORD
BioCentury | Jul 14, 2022
Management Tracks
New CEO at Deerfield-backed Apertura
Plus 10x Genomics hires Wilbur to head commercial, and updates from Immune-Onc, PathAI, Sherlock and more
BioCentury | May 18, 2021
Finance
May 18 Quick Takes: Temasek backs Wilson, Yamada to form G2 Bio; plus PathAI, Interius, Vedere II and more
Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson.
BioCentury | Apr 25, 2019
Clinical News
Gilead looks towards NASH combo data after selonsertib fails in second Phase III
Items per page:
1 - 6 of 6